Single-cell gene expression patterns in the brain, and evidence from follow-up experiments, reveal many shared cellular and molecular similarities that could be targeted for potential treatment.
Professor Ernest Fraenkel has decoded fundamental aspects of Huntington’s disease and glioblastoma, and is now using computation to better understand amyotrophic lateral sclerosis.
Seed projects, posters represent a wide range of labs working on technologies, therapeutic strategies, and fundamental research to advance understanding of age-related neurodegenerative disease.
A machine-learning method finds patterns of health decline in ALS, informing future clinical trial designs and mechanism discovery. The technique also extends to Alzheimer’s and Parkinson’s.
Competitive seed grants launch yearlong investigations of novel hypotheses about potential causes, biomarkers, treatments of Alzheimer’s and ALS.
How 3D-printed models of neuronal axons could accelerate development of new therapies to treat neurodegenerative disorders.
Pison, founded by Dexter Ang ’05, enables people to control digital interfaces, such as their phones, through brain signals.
Researchers have designed a skin-like device that can measure small facial movements in patients who have lost the ability to speak.
3-D tissue model replicates the motor neuron connections affected by amyotrophic lateral sclerosis.
Biophysicist will investigate the biology of RNA aggregation.
Study in worms reveals gene loss can lead to accumulation of waste products in cells.
New chip could help test drugs for ALS, other neuromuscular disorders.
With support from the MIT Sandbox Innovation Fund Program, an MIT spinoff is creating assistive technology for people with ALS.
Associate Professor Ernest Fraenkel uses biological network modeling to identify new targets for disease.
Annual poster session showcases recent work on biological effects of exposure to environmental agents.